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Abstract
Background: The neuroleptic malignant syndrome is an uncommon but dangerous complication characterized by
hyperthermia, autonomic dysfunction, altered mental state, hemodynamic dysregulation, elevated serum creatine
kinase, and rigor. It is most often caused by an adverse reaction to anti-psychotic drugs or abrupt discontinuation
of neuroleptic or anti-parkinsonian agents. To the best of our knowledge, it has never been reported following the
common practice of discontinuation of anti-parkinsonian drugs during the pre-operative preparation for deep brain
stimulation surgery for Parkinson’s disease.
Case presentation: We present the first case of neuroleptic malignant syndrome associated with discontinuation
of anti-parkinsonian medication prior to deep brain stimulation surgery in a 54-year-old Caucasian man.
Conclusion: The characteristic neuroleptic malignant syndrome symptoms can be attributed to other, more
common causes associated with deep brain stimulation treatment for Parkinson’s disease, thus requiring a high
index of clinical suspicion to timely establish the correct diagnosis. As more centers become eligible to perform
deep brain stimulation, neurologists and neurosurgeons alike should be aware of this potentially fatal complication.
Timely activation of the deep brain stimulation system may be important in accelerating the patient’s recovery.
Introduction
Neuroleptic malignant syndrome (NMS) is a rare but
potentially fatal disorder, with a mortality rate between
10% and 30%. It is characterized by fever, severe rigidity,
autonomic instability, and an altered level of conscious-
ness [1]. We report a unique case of NMS following the
discontinuation of anti-parkinsonian drugs during the
pre-operative preparation for deep brain stimulation
(DBS) surgery.
Case presentation
A 54-year-old Caucasian man with a 14-year history of
Parkinson’s disease (PD) was scheduled for DBS of the
sub-thalamic nucleus (STN) bilaterally. His anti-parkinso-
nian medication consisted of 600 mg/day levodopa, 125
mg/day carbidopa, 1200 mg/day entacapone, and 0.54 mg/
day pramipexole. This regimen was discontinued 18 hours
prior to the DBS procedure, according to our standard
protocol, to avoid medication-induced dyskinesias during
surgery and to allow for the patient to be in an off-state,
thus maximizing the clinical information gained by intra-
operative stimulation [2]. The procedure itself was
uneventful, with implantation of the DBS electrodes in the
STN bilaterally (Medtronic 3389 electrodes; Medtronic,
Minneapolis, MN, USA). Three hours post-operatively the
patient developed tremor, muscle rigidity, and high fever
resistant to common anti-pyretic drugs (paracetamol 1 g).
The tremor and rigidity were attributed to PD and 200 mg
levodopa three times daily was administered through a
nasogastric tube. Systemic and central nervous system
infection were also considered in the differential diagnosis;
however, cerebrospinal fluid analysis, a chest X-ray, and
blood and urine cultures were all within normal limits. A
subsequent brain magnetic resonance imaging scan
depicted no intracranial pathology and confirmed optimal
lead placement. Twelve hours postoperatively the patient’s
PD features worsened: He developed severe axial and
appendicular rigidity, coarse resting tremor, and prolonged
spasms of the extremities.
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His temperature had risen to 40°C, and his blood pres-
sure had increased to 165/94 mmHg. A new laboratory
investigation showed leukocytosis (leukocyte count,
19.4 × 109/L with a shift to the left (neutrophil count,
167 × 109/l). His serum levels of creatine kinase (CK)
were markedly elevated to 1500 U/l with a normal CK-
MB fraction, and his cardiac troponin levels were normal,
indicating that the CK elevation was not of cardiac origin.
At that point, the diagnosis of NMS was established on
the basis of the clinical examination and the laboratory
findings. Malignant hyperthermia was excluded after a
negative caffeine-halothane contracture test [3]. The
patient was intubated and transferred to the intensive
care unit (ICU). Treatment by intravenous administration
of 3 mg/kg/day dantrolene, 600 mg/day levodopa, and 60
mg apomorphine was initiated. After copious ICU treat-
ment, the patient was extubated on the ninth post-opera-
tive day. Fifteen days post-operatively he still appeared
lethargic and confused. The DBS device was conse-
quently activated on the 20th post-operative day, as it
was considered that it could accelerate the patient’s
recovery. Indeed, after DBS activation, the patient
showed a good recovery pace and was discharged from
the hospital on the 32nd post-operative day. At his six-
month follow-up examination, he demonstrated an over-
all improvement of 15% in the Unified Parkinson Disease
Rating Scale.
Discussion
Discontinuation of anti-parkinsonian medication is a
common practice prior to DBS surgery. It is known, how-
ever, that reduction of dopaminergic drugs can induce
NMS. The pitfall lies in that all of the characteristic NMS
symptoms can be attributed to other, more common
causes associated with DBS performed in patients with
PD, thus requiring a high index of clinical suspicion to
establish the correct diagnosis in a timely manner. In par-
ticular, muscle rigidity and autonomic instability are very
common in patients with PD and can be attributed to
relevant drug modifications prior to surgery. Changes in
cognition and delirium are also very common after DBS,
especially when the STN is involved [4]. Fever and leuko-
cytosis can be attributed to the procedure itself or to
CNS infection. The activation of the DBS system was a
matter of debate, as there were no similar cases reported
in the literature. It was finally activated on the 20th post-
operative day, after the patient had been extubated (sti-
mulation settings were monopolar stimulation, pulse
width 90 microseconds, frequency 130 Hz, amplitude
1.5 mV bilaterally, active contacts 1 and 5, right and left
side, respectively). At that point, he appeared confused,
drowsy, and disorganized with a very slow recovery
speed. It was our impression that the activation of
the DBS system significantly accelerated the patient’s
recovery, allowing for swift mobilization and intensive
physiotherapy.
Conclusion
This is the first case report of NMS associated with DBS.
Although this complication is not directly related to the
procedure itself, neurosurgeons and neurologists should
be vigilant when discontinuing anti-parkinsonian medica-
tion prior to surgery. As the number of DBS procedures
for PD increases and smaller neurosurgical centers
become eligible to perform the procedure, the medical
community should be aware of this potentially fatal com-
plication, which can disguise itself within the clinical
manifestations of the underlying pathology (PD) or the
provided treatment (DBS). Should this complication
arise, the optimal timing for DBS system activation
remains to be established. Nonetheless, this case report
supports the notion that stimulation may accelerate the
patient’s recovery.
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